The FDA's approval of Alhemo (concizumab-mtci) revolutionizes hemophilia treatment, offering a simpler, subcutaneous injection for better bleed control and patient independence.

Kedrion Biopharma receives US FDA orphan drug designation for Coagadex to treat acquired Factor X deficiency: Fort Lee, New Jersey Thursday, July 31, 2025, 15:00 Hrs [IST] Kedrion ...

Be Biopharma, Inc. ("Be Bio" or "the Company"), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the first participant was ...

New research from Stellenbosch University suggests a potential link between myalgic encephalomyelitis/chronic fatigue ...

In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement ...

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Studies suggest that as many as one in ten of us look to the growing army of chatbots powered by artificial intelligence, or ...

Medically reviewed by David Ozeri, MD Acute (short-term) inflammation occurs when your immune system sends inflammatory cells ...

With the launch of a U.S. trial, a treatment using the B-cell medicine BE-101 has been given to a hemophilia B patient for ...

The fitment factor—the multiplication unit used for revision—is likely to be in the range of 1.83 to 2.46, the brokerage said in the note dated July 9.

As per Ambit Capital's estimated fitment factor under the 8th Pay Commission, a base salary of Rs 50,000 can rise up to Rs 1.23 lakh.

The Global Coagulation Factor Deficiency Market Report (2025-2035) highlights advances in treatment options for blood clotting disorders like Hemophilia A, Hemophilia B, and Von Willebrand Disease.